Sionna Therapeutics (NASDAQ:SION) Stock Price Down 5.6% – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION) traded down 5.6% during trading on Thursday . The stock traded as low as $15.05 and last traded at $15.56. 68,373 shares were traded during trading, a decline of 66% from the average session volume of 201,986 shares. The stock had previously closed at $16.48.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 price target for the company. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating for the company. Finally, Guggenheim assumed coverage on Sionna Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 price target for the company.

Sionna Therapeutics Stock Up 4.0 %

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.